Patent · US Expired

Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators

US6548547B1 · kind B1 · utility

9Cited by

5References

6Claims

0Family size

Assignee

Aventis Pharma Deutschland GmbH · DE

Inventors

Ursula Schindler · Bad Soden, DE
Karl Schoenafinger · Alzenau, DE
Hartmut Strobel · Liederbach, DE

Key dates

Filing date	Mar 8, 2001
Grant date	Apr 15, 2003
Priority date	—
Expiry date	Mar 8, 2021

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F9/3882
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to compounds of the formula I in which A1, A2, R2 and R3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.